Radient Pharmaceuticals, Provista Diagnostics deal

Radient entered into a letter of intent to acquire Provista (also known as Provista Life Sciences LLC) in a stock deal. Provista offers CLIA laboratory testing services, including its Biomarker Translation Test for breast cancer, LymPro Test to assist doctors in the diagnosis of Alzheimer's disease, RCP Test for ovarian, uterine and cervical cancer, and REDx to screen for mild cognitive impairment, AD and other forms of dementia. Radient said the deal will broaden its in vitro diagnostic testing business, which includes its marketed Onko-Sure test for cancer. In May, Radient granted Provista non-exclusive rights to use Onko-Sure. Financial terms were not disclosed (see BioCentury, May 17). ...